Abstract
This paper evaluates the data describing respiratory
syncytial virus (RSV) infection in infants and children
aged less than five years in NSW, and in particular
children aged less than one year. This younger age
group forms the primary target group for immunisation
against RSV and vaccine development is now well
advanced. The data outlined in this paper provide a
baseline for evaluating the burden of disease before
and after the introduction of a vaccine.
